{Reference Type}: Journal Article
{Title}: Plasma homocysteine level, estradiol level, and brain atrophy: a Mendelian randomization study.
{Author}: Gao W;Zhu WW;Yu YH;Wang J;
{Journal}: Cereb Cortex
{Volume}: 34
{Issue}: 3
{Year}: 2024 03 1
{Factor}: 4.861
{DOI}: 10.1093/cercor/bhae112
{Abstract}: Observational studies link elevated plasma homocysteine (Hcy) with vascular disease. Our aim was to assess the gender difference in the association between the plasma tHcy level and brain atrophy and identify the possible influencer. We employed Mendelian randomization (MR) to explore the causal relationship between plasma tHcy level, estradiol level, and brain atrophy.
A total of 687 patients with brain atrophy were included, and gender-specific subgroup analyses in association between tHcy and brain atrophy are conducted. From genome-wide association studies, we selected genetic variants (P < 5 × 10-8) for the plasma tHcy level and estradiol level. We investigated the degree of brain atrophy (including gray matter volume and total brain volume) in the UK biobank (n = 7,916). The inverse variance-weighted and several sensitivity MR regression analyses were carried out.
The plasma tHcy level was significantly associated with brain atrophy for females, but not for males. An MR study showed that there was little evidence of the causal link between elevated plasma tHcy and brain atrophy. On the other hand, we found evidence to support causality for genetically decreased estradiol with higher risk of brain atrophy. Furthermore, genetic predisposition to elevated plasma tHcy was associated with a lower estradiol level.
The influence of estradiol on the association between tHcy and brain atrophy deserves further investigation.